---
title: "Projecting the top 20 Big Pharma firms of FY2024"
description: "The pharmaceutical industry is experiencing significant shifts in its hierarchy, with Merck and Pfizer leading in projected revenues for FY2024. AstraZeneca, Eli Lilly, and Novo Nordisk are showing re"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/219886824.md"
published_at: "2024-11-17T06:16:36.000Z"
---

# Projecting the top 20 Big Pharma firms of FY2024

> The pharmaceutical industry is experiencing significant shifts in its hierarchy, with Merck and Pfizer leading in projected revenues for FY2024. AstraZeneca, Eli Lilly, and Novo Nordisk are showing remarkable growth rates, indicating a competitive transformation. AstraZeneca's revenue increased by 19% in the first nine months, prompting an upgrade in its growth guidance. Merck and Pfizer are also maintaining steady growth, despite challenges in the post-COVID landscape. The report outlines revenue projections for the top 20 Big Pharma firms, highlighting key financial metrics and growth expectations.

\[sizsus/Adobe Stock\]

The pharmaceutical industry’s traditional hierarchy is facing its strongest challenge in years, with projected 2024 revenues showing dynamic shifts among the leaders. While Merck ($63.9B) and Pfizer ($62.5B) hold the top spots, double-digit growth from AstraZeneca (+17.9%), Eli Lilly (+33.9%), and Novo Nordisk (+26.1%) signals an accelerating transformation in the sector’s competitive landscape.

The continued strength of the GLP-1 market continues to be a market disruptor, but the medications also face complex challenges in terms of accessibility, cost, and market penetration.

AstraZeneca was something of a surprise success story in a landscape where GLP-1 therapies loom large. Its strong product portfolio and performance across key therapeutic areas helped propel total revenue 19% to $39,182 million in the first nine months of the year. Oncology, Cardiovascular, Renal and Metabolism (CVRM), and Respiratory and Immunology (R&I) saw growth rates of 22%, 21%, and 24% respectively, complemented by 14% growth in rare disease. Key products like Farxiga and Enhertu contributed significantly, with growth rates of 34% and 60% respectively in Q3. AstraZeneca also announced a $2 billion investment in U.S. R&D and manufacturing, and navigated regulatory challenges in China. As a result, AstraZeneca upgraded its full-year 2024 guidance, projecting high teens percentage growth for both Total Revenue and Core EPS.

Leading 2024 in terms of overall revenue areMerck & Co., which continued to maintain a steady trajectory with projected worldwide sales between $63.6 billion and $64.1 billion, demonstrating approximately 5.8% to 6.6% annual growth. The company’s quarterly growth, however, has slowed, from 12% excluding foreign exchange in Q1 to 7% in Q3, indicating potential challenges even as Keytruda sales remain strong. Pfizer also continues to navigate a complex transition in a post-COVID landscape but the company had a standout third quarter despite anticipating an approximately 36% to 39% annual dip owing to decreased COVID-19 product sales.

Here are the full projections.

**Rank**

**Company**

**2023 Revenue**

**2024 Projection**

**Projected Growth**

**Key Financial Highlights**

1

Merck

$60.12B

$63.85B

+6.2%

Q1-Q3: 9%, 7%, 4% growth trajectory; Strong momentum ex-FX (Q1: 12%, Q3: 7%); Guidance: $63.6B-$64.1B

2

Pfizer

$58.50B

$62.50B

+6.8%

Q3 showing recovery: 31% growth; COVID impact factored into guidance; Recent guidance raise: $61.0B-$64.0B

3

AstraZeneca

$45.81B

$54.00B

+17.9%

Consistent high-teens growth (Q1-Q3: 19%, 17%, 21%); YTD: $39.18B (+19%); Strong momentum across quarters. Guidance in the ‘high teens.’

4

Roche

$51.45B

$53.50B

+4.0%

Q1-Q3: Accelerating growth (2%, 5%, 9%); YTD: 6% CER growth; Mid-single-digit guidance

5

Johnson & Johnson

$50.93B

$53.48B

+5.0%

Pharma segment steady at 5.5% growth

6

Sanofi

$46.59B

$52.97B

+13.7%

Accelerating growth (5.7%, 10.2%, 15.7%); Strong Q3: €13.44B; Raised EPS guidance

7

Novartis

$45.44B

$49.94B

+9.9%

Steady growth (7%, 9%, 10%); Low double-digit guidance; Strong operating income

8

Bristol-Myers Squibb

$45.01B

$47.44B

+5.4%

Consistent growth (5%, 9%, 8%); ~5% revenue growth guidance; Solid Q2 performance at 9%

9

Eli Lilly

$34.12B

$45.70B

+33.9%

Market leading Q2/Q3 (36%, 20%); Clear guidance: $45.4B-$46.0B; Strong momentum in key products

10

Novo Nordisk

$33.71B

$42.50B

+26.1%

Q3: 21% growth; Wegovy sales up 84%; Ozempic sales up 28%; Guidance: 23-27% growth

11

GSK

$37.73B

$40.23B

+6.6%

Strong H1 (10%, 13%); Q3 moderation to 2%; Guidance: 7-9% turnover growth

12

Amgen

$28.19B

$33.30B

+18.1%

Consistent 20%+ growth; Q1-Q3: 22%, 20%, 23%; Guidance: $32.8B-$33.8B

13

Takeda

$30.34B

$30.52B

+0.6%

Strong H1: 14.1%, 13.4% growth; Raised forecast to ¥4,480B; Better than initial flat guidance

14

Gilead

$27.12B

$27.95B

+3.1%

Q3: 7% growth; Key products growing (Biktarvy +13%); Guidance: $27.8B-$28.1B

15

Bayer AG

$17.78B

$17.23B

\-3.0%

Q3 challenges: 3.6% revenue decline; EBITDA down 25.8%; Cautious 2025 outlook

16

Teva

$15.85B

$16.30B

+2.8%

Q3: 13% USD growth; Strong product performance; Guidance: $16.1B-$16.5B

17

Otsuka

$14.32B

$15.25B

+6.5%

Q3: 17% YoY growth; ¥1,730.1B forecast; Positive profit outlook

18

Viatris

$15.43B

$15.05B

\-2.5%

Q3: 3% growth (divestiture-adjusted); Guidance: $14.6B-$15.1B; EBITDA: $5.0B-$5.3B target

19

CSL

$13.31B

$14.80B

+11.2%

CSL Behring: 14% growth; Seqirus: 4% growth; Strong NPATA growth

20

Regeneron

$13.12B

$13.85B

+5.6%

Q3: 11% growth; Dupixent sales +23%; Product sales guidance: $27.8B-$28.1B

### Methodology

The revenue projections for 2024 were initially based on financial figures derived from the trailing four quarters of reported revenue and from the companies’ guidance. Data from company reports and finbox.com. For companies offering direct guidance, projections were aligned with the midpoint of the guidance ranges. For companies providing growth-rate guidance rather than specific revenue targets, projections were calculated using the implied growth ranges.

Diversified companies required segment-specific adjustments to accurately estimate pharmaceutical revenue. These adjustments included segment contributions of 63.67% for Johnson & Johnson, 71.6% for Roche, 33.8% for Bayer, 37.6% for Merck KGaA, and 13.0% for Abbott.

* * *

* * *

### Related Stocks

- [PFE.US - Pfizer](https://longbridge.com/en/quote/PFE.US.md)
- [LLY.US - Eli Lilly](https://longbridge.com/en/quote/LLY.US.md)
- [NVO.US - Novo Nordisk AS](https://longbridge.com/en/quote/NVO.US.md)
- [MRK.US - Merck](https://longbridge.com/en/quote/MRK.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 诺和诺德公司董事会提议再次选举 Lars Rebien Sorensen 担任主席 | 诺和诺德公司董事会提议重新选举拉斯·瑞比恩·索伦森为董事长 | [Link](https://longbridge.com/en/news/276440991.md) |
| DELL, SPOT, UNH：全球最大的对冲基金正在市场中寻找抄底机会 | 桥水基金（Bridgewater Associates），全球最大的对冲基金，管理资产达 1360 亿美元，在 2025 年第四季度对表现不佳的股票进行了重大投资，包括戴尔（DELL）、Spotify（SPOT）和联合健康（UnitedHe | [Link](https://longbridge.com/en/news/276384705.md) |
| Puzo Michael J 在诺和诺德公司 $NVO 拥有价值 32 万美元的股票持仓 | Puzo Michael J 在第三季度大幅减持了 Novo Nordisk A/S (NYSE:NVO) 的股份，减少幅度达到 86.9%，目前持有 5,775 股，价值 320,000 美元。其他机构投资者也调整了他们的持仓，True  | [Link](https://longbridge.com/en/news/276447697.md) |
| 诺和诺德公司提议任命两名新的董事会成员 | 丹麦制药公司诺和诺德公司提议在 3 月 26 日于哥本哈根举行的年度股东大会上新增三名董事会成员。提议的成员包括海伦娜·萨克森、扬·范·德·温克尔和拉莫娜·塞奎拉。萨克森此前已宣布辞去 Sobi 的职务以加入诺和诺德。还提议重新选举董事长拉 | [Link](https://longbridge.com/en/news/276442777.md) |
| 诺和诺德公司：将在 Ozempic 和 Wegovy 专利到期时准备好替代产品 - Berlingske | 丹麦制药公司诺和诺德计划在其药物 Ozempic 和 Wegovy 的专利于 2031 年在欧洲和 2032 年在美国到期时，准备好替代药物。研究负责人马丁·霍尔斯特·朗格表示，某些临床试验中的候选药物可能会在 2030 年前提交审批。有关 | [Link](https://longbridge.com/en/news/276314777.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
